<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04227600</url>
  </required_header>
  <id_info>
    <org_study_id>JR-171-101</org_study_id>
    <nct_id>NCT04227600</nct_id>
  </id_info>
  <brief_title>A Study of JR-171 in Patients With Mucopolysaccharidosis I</brief_title>
  <official_title>Phase I/II Study of JR-171 ㏌ Patients With Mucopolysaccharidosis Type I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JCR Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JCR Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/II, open-label, multicenter, multinational (Japan, Brazil and US),designed to&#xD;
      evaluate the safety, pharmacokinetics and explore the efficacy for the treatment of&#xD;
      mucopolysaccharidosis type I (MPS I).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>13 Week</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>13 Week</time_frame>
    <description>Laboratory tests (hematology, biochemistry, serum iron tests, and urinalysis)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>13 Week</time_frame>
    <description>Vital signs (pulse rate, body temperature, blood pressure, respiratory rate and percutaneous oxygen saturation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>13 Week</time_frame>
    <description>12-lead electrocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>13 Week</time_frame>
    <description>Antibodies [anti-human-α-L-iduronidase (anti-IDUA) and anti-JR-171 antibodies]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>13 Week</time_frame>
    <description>Infusion associated reaction (IAR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of plasma drug concentration</measure>
    <time_frame>Part1: 1,2,3,4 week, Part2: 1,4,12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameter</measure>
    <time_frame>Part1: 1,2,3,4 week, Part2: 1, 4, 12 week</time_frame>
    <description>Maximum Plasma Concentration[Cmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameter</measure>
    <time_frame>Part1: 1,2,3,4 week, Part2: 1, 4, 12 week</time_frame>
    <description>Area Under the Curve from time zero to the last blood sampling time point[AUC0-t]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameter</measure>
    <time_frame>Part1: 1,2,3,4 week, Part2: 1, 4, 12 week</time_frame>
    <description>Area Under the Curve from time zero to infinity [AUC0-∞]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameter</measure>
    <time_frame>Part1: 1,2,3,4 week, Part2: 1, 4, 12 week</time_frame>
    <description>Time to reach maximum plasma concentration [tmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameter</measure>
    <time_frame>Part1: 1,2,3,4 week, Part2: 1, 4, 12 week</time_frame>
    <description>Elimination half-life [t1/2]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameter</measure>
    <time_frame>Part1: 1,2,3,4 week, Part2: 1, 4, 12 week</time_frame>
    <description>Elimination rate constant [kel]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetic parameter</measure>
    <time_frame>Part1: 1,2,3,4 week, Part2: 1, 4, 12 week</time_frame>
    <description>Mean residence time from time zero to the last blood sampling time point [MRT0-t]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Drug concentration in Cerebrospinal Fluid.</measure>
    <time_frame>Part1: Baseline, 4 week Part2: Baseline, 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heparan Sulfate Levels in Cerebrospinal Fluid</measure>
    <time_frame>Part 1: Baseline, 4 week Part 2: Baseline, 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heparan Sulfate Levels in Serum</measure>
    <time_frame>Part 1: Baseline, 2,3,4,5 week Part2: Baseline, 2, 4, 6, 8, 10, 12, 13 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heparan Sulfate Levels in Urinary</measure>
    <time_frame>Part 1: Baseline, 2,3,4,5 week Part2: Baseline, 2, 4, 6, 8, 10, 12, 13 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatan Sulfate Levels in Cerebrospinal Fluid</measure>
    <time_frame>Part 1: Baseline, 4 week Part 2: Baseline, 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatan Sulfate Levels in Serum</measure>
    <time_frame>Part 1: Baseline, 2,3,4,5 week Part2: Baseline, 2, 4, 6, 8, 10, 12, 13 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Dermatan Sulfate Levels in Urinary</measure>
    <time_frame>Part 1: Baseline, 2,3,4,5 week Part2: Baseline, 2, 4, 6, 8, 10, 12, 13 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Opening pressure in Cerebrospinal Fluid</measure>
    <time_frame>Part 1: Baseline, 4 week Part 2: Baseline, 12 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Liver Volume.</measure>
    <time_frame>Part 1: Baseline, 5 week Part 2: Baseline, 13 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Spleen Volume.</measure>
    <time_frame>Part 1: Baseline, 5 week Part 2: Baseline, 13 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Echocardiography.</measure>
    <time_frame>Part 1: Baseline, 5 week Part 2: Baseline, 13 week</time_frame>
    <description>left ventricular posterior wall thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Echocardiography.</measure>
    <time_frame>Part 1: Baseline, 5 week Part 2: Baseline, 13 week</time_frame>
    <description>interventricular septal thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Echocardiography.</measure>
    <time_frame>Part 1: Baseline, 5 week Part 2: Baseline, 13 week</time_frame>
    <description>left ventricular mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Echocardiography.</measure>
    <time_frame>Part 1: Baseline, 5 week Part 2: Baseline, 13 week</time_frame>
    <description>left ventricular fractional shortening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Echocardiography.</measure>
    <time_frame>Part 1: Baseline, 5 week Part 2: Baseline, 13 week</time_frame>
    <description>left ventricular ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Echocardiography.</measure>
    <time_frame>Part 1: Baseline, 5 week Part 2: Baseline, 13 week</time_frame>
    <description>E/A ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 6-minute Walk Test Distance.</measure>
    <time_frame>Part 2: Baseline, 13 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in BVMT-R</measure>
    <time_frame>Part 2: Baseline, 13 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HVLT-R</measure>
    <time_frame>Part 2: Baseline, 13 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in T.O.V.A.</measure>
    <time_frame>Part 2: Baseline, 13 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PedsQL-FIM</measure>
    <time_frame>Part 2: Baseline, 13 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Mucopolysaccharidosis I</condition>
  <arm_group>
    <arm_group_label>Part1 JR-171</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: JR-171 IV infusion, dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2 JR-171</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: JR-171 IV infusion, dose escalation, low dose, high dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JR-171</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Part1 JR-171</arm_group_label>
    <arm_group_label>Part2 JR-171</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A patient aged 18 years or older in Part 1 or any age in Part 2, at the time of&#xD;
             informed consent&#xD;
&#xD;
          -  A patient from whom written informed consent can be obtained. If the patient is aged&#xD;
             under 18 years (20 years in case of Japan) at the time of assent or willingness to&#xD;
             participate in the study cannot be confirmed due to MPS I-related intellectual&#xD;
             disability, informed permission from the patient's legally acceptable representative&#xD;
             (e.g. his/her parents or guardians) need to be obtained instead of his/her consent.&#xD;
             Even in this case, written informed consent or assent should be obtained from the&#xD;
             patient, wherever possible&#xD;
&#xD;
          -  A patient diagnosed with MPS I based on any one of the following criteria:&#xD;
&#xD;
          -  Activity of IDUA enzyme below 10% of lower reference level in leucocytes or cultured&#xD;
             skin fibroblasts, AND increased age-related urinary levels of GAGs (before enzyme&#xD;
             replacement therapy)&#xD;
&#xD;
          -  Activity of IDUA enzyme below 10% of lower reference level in leucocytes or cultured&#xD;
             skin fibroblasts, AND presence of one pathogenic mutation in each of the alleles of&#xD;
             the IDUA gene&#xD;
&#xD;
          -  Increased age-related urinary levels of GAGs (before enzyme replacement therapy), AND&#xD;
             presence of one pathogenic mutation in each of the alleles of the IDUA gene&#xD;
&#xD;
          -  A patient diagnosed as having no or mild MPS I-related intellectual disability (able&#xD;
             to report their own subjective symptoms) by the principal investigator or&#xD;
             subinvestigator (Part 1 only)&#xD;
&#xD;
          -  A patient who has received laronidase continuously for at least 12 weeks and has&#xD;
             received laronidase on a stable dosage for 2 weeks immediately before the initial&#xD;
             administration of JR-171, except for a laronidase naïve patient or a patient who has&#xD;
             previously been treated by HSCT)&#xD;
&#xD;
          -  Female patient or male patient whose co-partner is of child-bearing potential agrees&#xD;
             to use a medically accepted, highly effective method of contraception, such as&#xD;
             spermatocidal gel plus condom, an intrauterine device or oral contraceptives until one&#xD;
             month after the final administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A patient who received gene therapy treatment&#xD;
&#xD;
          -  A patient who, in the opinion of the principal investigator or subinvestigator, cannot&#xD;
             undergo lumbar puncture, including those who have a difficulty in taking a position&#xD;
             for lumbar puncture due to joint contracture and those who are likely to develop&#xD;
             dyspnea during lumbar puncture&#xD;
&#xD;
          -  A patient who is pregnant or lactating&#xD;
&#xD;
          -  A patient who has developed serious drug allergy or hypersensitivity to any drugs, in&#xD;
             the opinion of the principal investigator or subinvestigator, is inappropriate for&#xD;
             participation in the study&#xD;
&#xD;
          -  A patient who has received another investigational product within 12 months before&#xD;
             enrollment in the study&#xD;
&#xD;
          -  A patient who, in the opinion of the principal investigator or subinvestigator, is&#xD;
             ineligible to participate in the study out of consideration for the participant&#xD;
             safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JCR Pharmaceuticals Co., Ltd.</last_name>
    <phone>+81-(0)797-32-8582</phone>
    <email>kaihatsu@jcrpharm.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Giugliani</last_name>
      <phone>+5551-3359-6340</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Genética e Erros Inatos do Metabolismo - IGEIM</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Maria Martins</last_name>
      <phone>+5511-5081-9620</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fukuoka Children's Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryutaro Kira</last_name>
      <phone>+81-92-682-7000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kochi Medical School Hospital</name>
      <address>
        <city>Nankoku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takashi Hamazaki</last_name>
      <phone>+81-6-6645-2121</phone>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 27, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

